IF 5.7 3区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
International journal of molecular medicine Pub Date : 2025-06-01 Epub Date: 2025-04-04 DOI:10.3892/ijmm.2025.5526
Hui Zhi, Xiaoyu Wang, Yujia Chen, Zenglin Cai, Jingwei Li, Dongkai Guo
{"title":"Ceftriaxone affects ferroptosis and alleviates glial cell activation in Parkinson's disease.","authors":"Hui Zhi, Xiaoyu Wang, Yujia Chen, Zenglin Cai, Jingwei Li, Dongkai Guo","doi":"10.3892/ijmm.2025.5526","DOIUrl":null,"url":null,"abstract":"<p><p>Parkinson's disease (PD) is the second most common neurodegenerative disorder, which is characterized by the death of dopaminergic neurons. It has been reported that ceftriaxone (CEF) exerts promising effects on alleviating dopaminergic neuron death in PD models. However, the neuroprotective mechanisms of CEF in PD have not been well understood. In the present study, to investigate the neuroprotective effects of CEF through western blot and immunofluorescence assays, two <i>in vivo</i> models were established, namely the 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine (MPTP)‑ and lipopolysaccharide (LPS)‑induced models. Additionally, three <i>in vitro</i> models were used to explore the neuroprotective mechanisms of CEF, namely the 1‑methyl‑4‑phenylpyridinium ion (MPP+)‑induced dopaminergic neuron injury, LPS‑induced microglia activation and TNFα‑induced astrocyte activation models, with key insights derived from western blot and qPCR experiments. The <i>in vivo</i> studies demonstrated that CEF exerted neuroprotective effects and reduced glial cell activation. Additionally, CEF reversed the reduction of tyrosine hydroxylase and suppressed the activation of microglia and astrocytes. Furthermore, the <i>in vitro</i> experiments revealed that CEF could display both direct and indirect neuroprotective effects and could directly alleviate MPP+‑induced neuronal toxicity and suppress the activation of microglia and astrocytes. In addition, CEF indirectly reduced neuronal injury caused by conditioned medium from activated microglia and astrocytes. Mechanistic studies revealed that CEF inhibited the ferroptosis pathway via regulating the expression of solute carrier family 7 member 11 and glutathione peroxidase 4 in a non‑cell‑specific manner. Via inhibiting ferroptosis, CEF could directly protect dopaminergic neurons and prevent glial cell activation, and indirectly impair neurons. In conclusion, the results of the current study highlighted the potential research and therapeutic value of CEF in regulating ferroptosis in PD.</p>","PeriodicalId":14086,"journal":{"name":"International journal of molecular medicine","volume":"55 6","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of molecular medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3892/ijmm.2025.5526","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/4 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

帕金森病(PD)是第二大常见的神经退行性疾病,其特征是多巴胺能神经元的死亡。有报道称,头孢曲松(CEF)在帕金森病模型中具有缓解多巴胺能神经元死亡的良好效果。然而,头孢曲松在帕金森病中的神经保护机制尚不十分清楚。本研究建立了两种体内模型,即1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)和脂多糖(LPS)诱导的模型,通过Western印迹和免疫荧光检测研究CEF的神经保护作用。此外,还使用了三种体外模型来探索 CEF 的神经保护机制,即 1-甲基-4-苯基吡啶鎓离子(MPP+)诱导的多巴胺能神经元损伤模型、LPS 诱导的小胶质细胞活化模型和 TNFα 诱导的星形胶质细胞活化模型,并从 Western 印迹和 qPCR 实验中获得了重要见解。体内研究表明,CEF 具有神经保护作用,并能减少神经胶质细胞的活化。此外,CEF 还能逆转酪氨酸羟化酶的减少,抑制小胶质细胞和星形胶质细胞的活化。此外,体外实验还发现,CEF 具有直接和间接的神经保护作用,可直接减轻 MPP+ 诱导的神经元毒性,抑制小胶质细胞和星形胶质细胞的活化。此外,CEF 还能间接减轻活化的小胶质细胞和星形胶质细胞的条件培养基对神经元的损伤。机理研究发现,CEF 通过调节溶质运载家族 7 成员 11 和谷胱甘肽过氧化物酶 4 的表达,以非细胞特异性的方式抑制了铁突变途径。通过抑制铁氧化,CEF 可直接保护多巴胺能神经元,防止神经胶质细胞活化,并间接损伤神经元。总之,本研究的结果凸显了 CEF 在调控帕金森病铁突变方面的潜在研究和治疗价值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Ceftriaxone affects ferroptosis and alleviates glial cell activation in Parkinson's disease.

Parkinson's disease (PD) is the second most common neurodegenerative disorder, which is characterized by the death of dopaminergic neurons. It has been reported that ceftriaxone (CEF) exerts promising effects on alleviating dopaminergic neuron death in PD models. However, the neuroprotective mechanisms of CEF in PD have not been well understood. In the present study, to investigate the neuroprotective effects of CEF through western blot and immunofluorescence assays, two in vivo models were established, namely the 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine (MPTP)‑ and lipopolysaccharide (LPS)‑induced models. Additionally, three in vitro models were used to explore the neuroprotective mechanisms of CEF, namely the 1‑methyl‑4‑phenylpyridinium ion (MPP+)‑induced dopaminergic neuron injury, LPS‑induced microglia activation and TNFα‑induced astrocyte activation models, with key insights derived from western blot and qPCR experiments. The in vivo studies demonstrated that CEF exerted neuroprotective effects and reduced glial cell activation. Additionally, CEF reversed the reduction of tyrosine hydroxylase and suppressed the activation of microglia and astrocytes. Furthermore, the in vitro experiments revealed that CEF could display both direct and indirect neuroprotective effects and could directly alleviate MPP+‑induced neuronal toxicity and suppress the activation of microglia and astrocytes. In addition, CEF indirectly reduced neuronal injury caused by conditioned medium from activated microglia and astrocytes. Mechanistic studies revealed that CEF inhibited the ferroptosis pathway via regulating the expression of solute carrier family 7 member 11 and glutathione peroxidase 4 in a non‑cell‑specific manner. Via inhibiting ferroptosis, CEF could directly protect dopaminergic neurons and prevent glial cell activation, and indirectly impair neurons. In conclusion, the results of the current study highlighted the potential research and therapeutic value of CEF in regulating ferroptosis in PD.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
International journal of molecular medicine
International journal of molecular medicine 医学-医学:研究与实验
CiteScore
12.30
自引率
0.00%
发文量
124
审稿时长
3 months
期刊介绍: The main aim of Spandidos Publications is to facilitate scientific communication in a clear, concise and objective manner, while striving to provide prompt publication of original works of high quality. The journals largely concentrate on molecular and experimental medicine, oncology, clinical and experimental cancer treatment and biomedical research. All journals published by Spandidos Publications Ltd. maintain the highest standards of quality, and the members of their Editorial Boards are world-renowned scientists.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信